Benzodiazepine Induced Neurological Dysfunction (BIND)

This module focuses on Benzodiazepine-Induced Neurological Dysfunction (BIND), featuring a physician-scientist and an author with lived experience who describe the experience from clinical and personal perspectives. They review underlying causes and symptoms of BIND, and they discuss the potential for long-term repercussions. Results from research studies are shared along with resources for medical support and symptom management.

 

Target Audience

MDs/DOs, Primary Care, Emergency Medicine , Hospitalist, Surgeons, OB/GYNs, Neurologist, Dentists and Oral Surgeons, Physical medicine and rehabilitation, Occupational medicine, Pharmacists, Nurse practitioners and other advanced- practice registered nurses, Physician assistants

 

Learning Objectives

Outline symptoms and life effects of benzodiazepine acute withdrawal and post-withdrawal Benzodiazepine Induced Neurological Dysfunction (BIND).

  Utilize a patient-centered approach in the deprescribing of benzodiazepines and managing post-withdrawal symptoms (BIND).

  Describe the importance of patient lived experience and peer support as it applies to benzodiazepine deprescribing and post-withdrawal symptoms (BIND).

 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
Course opens: 
03/19/2025
Course expires: 
03/19/2028
Rating: 
0

Dr. Alexis Ritvo is a board-certified addiction psychiatrist and assistant professor of psychiatry at University of Colorado (CU) School of Medicine. She also serves as the Medical Director for the Alliance for Benzodiazepine Best Practices. She has been the program director for the CU addiction psychiatry fellowship since July 2020. She is co-chair of the Benzodiazepine Action Work Group with the Colorado Consortium for Prescription Drug Abuse, which she co-founded with Dr. Steven Wright, the former medical director for the Alliance. She has a passion for psychotherapy, teaching and improving health systems and policies. Her professional goals are twofold: 1. to increase psychiatry resident’s competency in evaluating and treating substance use disorders and physical dependence to benzodiazepines in general outpatient psychiatry and 2. to improve patient access to psychiatric treatment for substance use disorders and physical dependence to benzodiazepines co-occurring with other psychiatric disorders.

D E Foster ("D") is founder of the support sites Easing Anxiety and uneven, host of the Benzo Free and uneven podcasts, and former co-chair and founding member of the Benzodiazepine Action Work Group. He is a published author on multiple research papers including the paper that introduced benzodiazepine-induced neurological dysfunction (BIND). Today, he spends his time as a global advocate for anxiety and benzodiazepine awareness, education, and support.

D has struggled with anxiety most of his life. In 2002, he was prescribed clonazepam (Klonopin) by his primary care physician for gastric distress, and he took the medication for 12 years without warning. His withdrawal experience was extreme and became the foundation for his book, Benzo Free: The World of Anti-Anxiety Drugs and the Reality of Withdrawal. D has been benzo-free since 2014, but he still deals with the lingering effects of BIND to this day.

Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Compass Healthcare Collaborative and Colorado Consortium for Prescription Drug Abuse Prevention. Compass Healthcare Collaborative is accredited by the IMS to provide continuing medical education for physicians.

Designation: Compass designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support: This activity was developed without support from any ineligible company. *The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.

Disclosure: Compass adheres to the Standards for Integrity and Independence in Accredited Continuing Education. The content of this activity is not related to products or the business lines of an ACCME-defined ineligible company. None of the planners or moderators for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing products used by or on patients.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
Please login or register to take this course.